ReviewMediators of inflammation2019
Mediators of Inflammation in Topical Therapy of Skin Cancers.
Review in Mediators of inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Emerging role of herbal nanogel formulations in skin cancer therapy: mechanistic insights and translational advances in nanomedicine.Journal of nanobiotechnology · 2026Review
- Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy.Pharmaceutics · 2026Review
- Prevalence of HPV in anal cancer: exploring the role of infection and inflammation.Infectious agents and cancer · 2024Review
- TLR3 activation mediates partial epithelial-to-mesenchymal transition in human keratinocytes.Life science alliance · 2024Article
- Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID.International journal of molecular sciences · 2024Review
- Role of Cannabinoids in Oral Cancer.International journal of molecular sciences · 2024Review
- Advanced lung cancer inflammation index is associated with prognosis in skin cancer patients: a retrospective cohort study.Frontiers in oncology · 2024Article
- Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches.Molecular cancer · 2023Review
- Looking into the Skin in Health and Disease: From Microscopy Imaging Techniques to Molecular Analysis.International journal of molecular sciences · 2023Article
- Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer.International journal of molecular sciences · 2023Review
- Amaryllidaceae alkaloids in skin cancer management: Photoprotective effect on human keratinocytes and anti-proliferative activity in melanoma cells.Journal of applied biomedicine · 2023Article
- Multilayer Methacrylate-Based Wound Dressing as a Therapeutic Tool for Targeted Pain Relief.Materials (Basel, Switzerland) · 2023Article
- The NLRP1 inflammasome in skin diseases.Frontiers in immunology · 2023Review
- Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments.Neoplasia (New York, N.Y.) · 2022Review
- Effects of Non-Opioid Analgesics on the Cell Membrane of Skin and Gastrointestinal Cancers.International journal of molecular sciences · 2022Review
- Pyroptosis-related genes regulate proliferation and invasion of pancreatic cancer and serve as the prognostic signature for modeling patient survival.Discover oncology · 2022Article
- Silver Nimesulide Complex in Bacterial Cellulose Membranes as an Innovative Therapeutic Method for Topical Treatment of Skin Squamous Cell Carcinoma.Pharmaceutics · 2022Article
- Global Trends in Research of NF-Journal of oncology · 2022Article
- Basal cell carcinoma-not always the 'good guy': Case report of a life-threatening basosquamous carcinoma and review of the literature.Experimental and therapeutic medicine · 2021Article
- Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma.Journal of personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taking into consideration that the immune system plays a very important role in the development of melanoma and non-melanoma skin cancers, which have a high prevalence in immunosuppressed patients and after prolonged ultraviolet radiation, the interest in developing novel therapies, in particular targeting the inflammation in cancer, has increased in the past years. The latest data suggest that therapies such as imiquimod (IMQ), ingenol mebutate (IM), 5-fluorouracil (5-FU), retinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been used with success in the topical treatment of some cancers. Herein, we review the topical treatment targeting the inflammation in skin cancer and the mechanisms involved in these processes. Currently, various associations have shown a superior success rate than monotherapy, such as systemic acitretin and topical IMQ, topical 5-FU with tretinoin cream, or IMQ with checkpoint inhibitor cytotoxic T lymphocyte antigen 4. Novel therapies targeting Toll-like receptor-7 (TLR-7) with higher selectivity than IMQ are also of great interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.